Edwards Lifesciences (EW) Total Non-Current Liabilities (2009 - 2026)

Edwards Lifesciences has reported Total Non-Current Liabilities for 18 years, with the latest figure at $2.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 1.41% year-over-year to $2.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (down 1.41% YoY), and the FY2025 full-year result was $2.9 billion, up 9.08% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $2.4 billion, down from $2.9 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $3.0 billion in Q3 2024, with the low at $2.1 billion in Q3 2022.
• Average Total Non-Current Liabilities over 5 years is $2.5 billion, with a median of $2.4 billion recorded in 2026.
• Year-over-year, Total Non-Current Liabilities slipped 16.31% in 2022 and climbed 25.41% in 2024.
• Tracing EW's Total Non-Current Liabilities over 5 years: stood at $2.2 billion in 2022, then advanced by 19.18% to $2.6 billion in 2023, then dropped by 0.93% to $2.6 billion in 2024, then increased by 9.08% to $2.9 billion in 2025, then slipped by 14.65% to $2.4 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.4 billion (Q1 2026), $2.9 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.

Peer Comparison